dana-farber cancer institute: guru sonpavde, md at asco gu21 (urothelial carcinoma)
Published 3 years ago • 69 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:25
bladder cancer research: immunotherapy outcomes | dana-farber cancer institute
-
1:44
dr. guru sonpavde on bladder cancer | dana-farber cancer institute
-
22:09
2024 asco bladder cancer highlights
-
31:39
genomearc webinar: pan cancer genes and variants - deniz duzenli
-
6:41
studies: prostate cancer patients do better with surgery
-
3:50
living with bladder cancer: dave’s story
-
2:22
bladder cancer advances | asco gu21
-
2:03
dana-farber cancer institute: mary-ellen taplin, md (asco gu21 prostate cancer)
-
1:23
bladder cancer research at esmo 2021
-
2:11
dr. mary-ellen taplin on treating prostate/gu cancers | dana-farber cancer institute
-
0:46
dr. sonpavde on the need for phase 3 data with pembrolizumab or atezolizumab in bladder cancer
-
6:57
dr. guru sonpavde
-
1:28
specialized care for esophageal and gastric cancers | dana-farber cancer institute
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
2:01
dr. guru sonpavde, dana-farber cancer institute, usa
-
2:17
how are clinical trials used in prostate cancer? | dana-farber cancer institute
-
2:35
welcome to dana-farber cancer institute
-
1:10
dr. sonpavde on the potential for neoadjuvant immunotherapy in bladder cancer
-
1:23
how is prostate cancer treated? | dana-farber cancer institute
-
12:59
vial presents: challenges in bladder cancer trials with dr. guru sonpavde